5-nitro-1-(4-nitro-phenyl)-dihydro-pyrimidine-2,4-dione | 59987-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 5-nitro-1-(4-nitro-phenyl)-dihydro-pyrimidine-2,4-dione
• 英文别名: 5-Nitro-1-(4-nitrophenyl)-1,3-diazinane-2,4-dione
• CAS: 59987-34-7
• 化学式: C₁₀H₈N₄O₆
• 分子量: 280.197
• InChiKey: BUMUBHQTPIIMCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：BROWN Dennis M.

  公开号：US20160045502A1

  公开（公告）日：2016-02-18

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

  本发明描述了一种改善先前受到治疗性能不佳限制的治疗剂的治疗效果的方法和组合物，通过改善单药疗法的功效或减少副作用。这种方法和组合物特别适用于芥子碱基烷基化剂，例如尿嘧啶芥和其类似物、衍生物或前药，包括6-甲基尿嘧啶芥和6-乙基尿嘧啶芥。
• COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS
  申请人：Orbus Therapeutics, Inc.

  公开号：US20190133985A1

  公开（公告）日：2019-05-09

  Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. Compositions and methods can include eflornithine or a derivative or analog of eflornithine, together with other agents such as conventional anti-neoplastic agents for treatment of glioma, inhibitors of polyamine transport, polyamine analogs, or S-adenosylmethionine decarboxylase inhibitors. Eflornithine or derivatives or analogs thereof can also be used to treat a range of non-glioma malignancies, including both malignancies of the central nervous system and other malignancies.
• [EN] THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS<br/>[FR] BÉNÉFICE THÉRAPEUTIQUE DE COMPOSÉS CHIMIQUES ADMINISTRÉS DE FAÇON SOUS-OPTIMALE
  申请人：BROWN DENNIS M

  公开号：WO2014168986A1

  公开（公告）日：2014-10-16

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.